Cencora, Inc. $COR Position Increased by Trustmark Bank Trust Department

Trustmark Bank Trust Department raised its stake in Cencora, Inc. (NYSE:COR) by 10.2% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 7,192 shares of the company’s stock after buying an additional 667 shares during the period. Trustmark Bank Trust Department’s holdings in Cencora were worth $2,157,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Atlantic Edge Private Wealth Management LLC grew its holdings in shares of Cencora by 70.0% in the 2nd quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock worth $25,000 after acquiring an additional 35 shares during the last quarter. Costello Asset Management INC acquired a new position in shares of Cencora in the 1st quarter valued at $28,000. Vermillion & White Wealth Management Group LLC boosted its position in shares of Cencora by 69.4% in the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 105 shares of the company’s stock valued at $31,000 after purchasing an additional 43 shares during the period. Hantz Financial Services Inc. increased its stake in Cencora by 712.0% in the 2nd quarter. Hantz Financial Services Inc. now owns 203 shares of the company’s stock worth $61,000 after purchasing an additional 178 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd acquired a new stake in Cencora during the 2nd quarter worth about $61,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Analyst Ratings Changes

Several brokerages have commented on COR. Weiss Ratings reiterated a “buy (b-)” rating on shares of Cencora in a report on Tuesday. Wall Street Zen downgraded shares of Cencora from a “buy” rating to a “hold” rating in a research report on Friday. JPMorgan Chase & Co. raised their price objective on shares of Cencora from $344.00 to $417.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 11th. UBS Group lifted their price objective on shares of Cencora from $380.00 to $415.00 and gave the stock a “buy” rating in a research report on Friday, November 7th. Finally, Mizuho increased their target price on Cencora from $340.00 to $380.00 and gave the company an “outperform” rating in a report on Thursday, November 6th. Nine equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat, Cencora has a consensus rating of “Moderate Buy” and a consensus price target of $371.09.

Insider Buying and Selling

In related news, CEO Robert P. Mauch sold 5,096 shares of the company’s stock in a transaction on Tuesday, November 18th. The shares were sold at an average price of $366.64, for a total value of $1,868,397.44. Following the completion of the sale, the chief executive officer directly owned 65,746 shares in the company, valued at approximately $24,105,113.44. This represents a 7.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Chairman Steven H. Collis sold 31,350 shares of the stock in a transaction on Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the transaction, the chairman directly owned 305,913 shares in the company, valued at $88,671,942.18. The trade was a 9.30% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 46,640 shares of company stock valued at $14,099,338 over the last quarter. Corporate insiders own 10.80% of the company’s stock.

Cencora Trading Up 0.1%

Shares of NYSE:COR opened at $368.93 on Friday. The firm has a fifty day moving average of $335.71 and a two-hundred day moving average of $307.63. The company has a quick ratio of 0.53, a current ratio of 0.90 and a debt-to-equity ratio of 3.64. Cencora, Inc. has a 12-month low of $223.92 and a 12-month high of $377.54. The firm has a market capitalization of $71.53 billion, a P/E ratio of 37.96, a price-to-earnings-growth ratio of 1.56 and a beta of 0.63.

Cencora (NYSE:COR) last released its quarterly earnings data on Wednesday, November 5th. The company reported $3.84 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.79 by $0.05. Cencora had a return on equity of 267.36% and a net margin of 0.60%.The firm had revenue of $83.73 billion during the quarter, compared to analysts’ expectations of $83.36 billion. During the same quarter last year, the firm earned $3.34 earnings per share. The business’s revenue for the quarter was up 5.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. On average, equities analysts expect that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 14th will be given a dividend of $0.60 per share. The ex-dividend date of this dividend is Friday, November 14th. This is a boost from Cencora’s previous quarterly dividend of $0.55. This represents a $2.40 annualized dividend and a yield of 0.7%. Cencora’s payout ratio is 30.19%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.